Argitalpenak (184) Ramón Lecumberri Villamediana argitalpenak

2024

  1. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis

    Cancers, Vol. 16, Núm. 9

  2. Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 143-152

  3. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  4. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  5. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

    Blood, Vol. 144, Núm. 8, pp. 873-887

  6. Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing

    Clinical and Translational Oncology

  7. Profilaxis de la enfermedad tromboembólica venosa en pacientes hospitalizados por patología médica desde los servicios de urgencias españoles: estudio PROTESU II

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 36, Núm. 4, pp. 271-280

  8. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  9. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  10. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 12, pp. 3581-3588

  2. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  3. Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning

    Thrombosis Research, Vol. 228, pp. 181-188

  4. Immunothrombosis: Molecular Aspects and New Therapeutic Perspectives

    Journal of Clinical Medicine, Vol. 12, Núm. 4

  5. Impacto del manejo en urgencias en la evolución de los pacientes con trombosis venosa superficial aislada de miembros inferiores: subanálisis del estudio ALTAMIRA

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 2, pp. 109-116

  6. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  7. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  8. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

  9. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline

    Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467

  10. When and How to Use Reversal Agents for Direct Oral Anticoagulants?

    Current Cardiology Reports, Vol. 25, Núm. 5, pp. 371-380